Nurix Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines for cancer and inflammatory diseases, has announced its participation in two major investor conferences in March 2025.

The company's leadership, including President and CEO Arthur T. Sands, M.D., Ph.D., and CFO Hans van Houte, will attend the Jefferies Biotech on the Beach Summit in Miami Beach for one-on-one meetings on March 11, 2025. They will also participate in the Barclays 27th Annual Global Healthcare Conference in Miami Beach, featuring a fireside chat on March 12, 2025, from 10:00-10:25 a.m. ET.

The fireside chat will be accessible through a live webcast on the Investors section of Nurix's website, with the recording available for 30 days following the event.

SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, and Hans van Houte, chief financial officer of Nurix, will participate in the following conferences in March.

• Jefferies Biotech on the Beach Summit, Miami Beach, FL
  • One-on-one meetings only: March 11, 2025
• Barclays 27th Annual Global Healthcare Conference, Miami Beach, FL
  • Fireside chat: March 12, 2025, from 10:00-10:25 a.m. ET

The fireside chat will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Contacts:

Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

When is Nurix Therapeutics (NRIX) presenting at the Barclays Healthcare Conference in March 2025?

Nurix Therapeutics will present a fireside chat at the Barclays Global Healthcare Conference on March 12, 2025, from 10:00-10:25 a.m. ET in Miami Beach.

How can investors access Nurix's (NRIX) Barclays Conference presentation?

Investors can access the fireside chat through a live webcast link available in the Investors section of the Nurix website. The recording will be available for 30 days after the event.

Which investor conferences is Nurix Therapeutics (NRIX) attending in March 2025?

Nurix is attending the Jefferies Biotech on the Beach Summit (March 11) and the Barclays 27th Annual Global Healthcare Conference (March 12) in Miami Beach.

What type of medicines is Nurix Therapeutics (NRIX) developing?

Nurix Therapeutics is developing targeted protein degradation medicines for the treatment of cancer and inflammatory diseases.